Last reviewed · How we verify

Ropivacaine + Ketamine — Competitive Intelligence Brief

Ropivacaine + Ketamine (Ropivacaine + Ketamine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic + NMDA receptor antagonist combination. Area: Anesthesia and Pain Management.

marketed Local anesthetic + NMDA receptor antagonist combination Voltage-gated sodium channels (ropivacaine); NMDA receptor (ketamine) Anesthesia and Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ropivacaine + Ketamine (Ropivacaine + Ketamine) — Aga Khan University. Ropivacaine blocks sodium channels to provide local anesthesia, while ketamine blocks NMDA receptors to provide analgesia and dissociative effects, together reducing pain and anesthetic requirements.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ropivacaine + Ketamine TARGET Ropivacaine + Ketamine Aga Khan University marketed Local anesthetic + NMDA receptor antagonist combination Voltage-gated sodium channels (ropivacaine); NMDA receptor (ketamine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic + NMDA receptor antagonist combination class)

  1. Aga Khan University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ropivacaine + Ketamine — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivacaine-ketamine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: